Biotech Values

[DewDiligence]

NANOV.OL reverse-merges with—(private)—APIM Therapeutics:

https://finance.yahoo.com/news/nordic-nanovector-apim-therapeutics-announce-025100000.html

… the former shareholders of APIM Therapeutics will own approximately 76% of the post-Transaction combined entity…and Nordic Nanovector's current shareholders will own approximately 24%. The Combined Entity will seek to retain the public listing on Oslo [stock exchange] and is expected to be renamed in due course.

… APIM Therapeutics, founded in 2010 in Trondheim, Norway, is a privately held, clinical stage Norwegian biotechnology company developing first-in-class molecules in oncology acting on a novel therapeutic intervention point with potential broad application across a wide range of cancers.

APIM's lead drug candidate ATX-101 is a first-in-class peptide targeting PCNA (Proliferating Cell Nuclear Antigen), a master regulator of cellular responses to stress and in tumour cell evasion from therapy. In preclinical experiments, ATX-101 has shown single agent activity in certain cancers and combinatorial activity with more than 25 different anti-cancer drugs in different tumour indications. A completed Phase 1 study in patients with advanced solid tumours has delivered encouraging clinical data and shown that ATX-101 has a highly favourable safety profile.

ATX-101 is currently being evaluated in platinum-sensitive ovarian cancer (Phase 1b/2a) and sarcoma (Phase 2) patients. Two pilot clinical studies, evaluating ATX-101 in platinum-resistant ovarian cancer and glioblastoma are expected to start in the second half of 2023.